Status:
COMPLETED
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
Lead Sponsor:
Boston Children's Hospital
Collaborating Sponsors:
Medical Research Council Unit, The Gambia
University of British Columbia
Conditions:
Newborn Vaccine Immunogenicity
Eligibility:
All Genders
Up to 1 years
Phase:
NA
Brief Summary
Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their opt...
Detailed Description
While the greatest number of vaccines is administered to the very young, vaccine preventable infections remain a major cause of morbidity and mortality, especially for the newborn. To improve vaccine-...
Eligibility Criteria
Inclusion
- \<24 hours of age
- \>37 weeks gestational age
- HIV unexposed
- Healthy (no malformations, normal temperature range and vital signs for age)
Exclusion
- Premature (\<37 weeks gestational age)
- Hepatitis B antigen-positive mother
- HIV-positive or HIV-exposed
- Febrile, unstable vital signs
Key Trial Info
Start Date :
September 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 29 2022
Estimated Enrollment :
911 Patients enrolled
Trial Details
Trial ID
NCT03246230
Start Date
September 6 2017
End Date
August 29 2022
Last Update
December 6 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Medical Research
Goroka, Eastern Highlands Province, Papua New Guinea
2
Medical Research Council Unit, The Gambia
Fajara, The Gambia, 000273